GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » Cyclically Adjusted Revenue per Share

ProPhase Labs (ProPhase Labs) Cyclically Adjusted Revenue per Share : $2.21 (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ProPhase Labs's adjusted revenue per share for the three months ended in Mar. 2024 was $0.201. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.21 for the trailing ten years ended in Mar. 2024.

During the past 12 months, ProPhase Labs's average Cyclically Adjusted Revenue Growth Rate was 2.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 27.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 17.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -0.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ProPhase Labs was 27.20% per year. The lowest was -17.40% per year. And the median was -6.10% per year.

As of today (2024-06-01), ProPhase Labs's current stock price is $5.16. ProPhase Labs's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $2.21. ProPhase Labs's Cyclically Adjusted PS Ratio of today is 2.33.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ProPhase Labs was 14.95. The lowest was 0.57. And the median was 1.88.


ProPhase Labs Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for ProPhase Labs's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs Cyclically Adjusted Revenue per Share Chart

ProPhase Labs Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.05 1.07 1.50 2.07 2.20

ProPhase Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 2.24 2.26 2.20 2.21

Competitive Comparison of ProPhase Labs's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, ProPhase Labs's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProPhase Labs's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, ProPhase Labs's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ProPhase Labs's Cyclically Adjusted PS Ratio falls into.



ProPhase Labs Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ProPhase Labs's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.201/131.7762*131.7762
=0.201

Current CPI (Mar. 2024) = 131.7762.

ProPhase Labs Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.106 100.560 0.139
201409 0.282 100.428 0.370
201412 0.581 99.070 0.773
201503 0.369 99.621 0.488
201506 0.137 100.684 0.179
201509 0.259 100.392 0.340
201512 -0.581 99.792 -0.767
201603 0.059 100.470 0.077
201606 0.060 101.688 0.078
201609 0.080 101.861 0.103
201612 0.045 101.863 0.058
201703 0.043 102.862 0.055
201706 0.112 103.349 0.143
201709 0.190 104.136 0.240
201712 0.338 104.011 0.428
201803 0.299 105.290 0.374
201806 0.281 106.317 0.348
201809 0.211 106.507 0.261
201812 0.354 105.998 0.440
201903 0.201 107.251 0.247
201906 0.143 108.070 0.174
201909 0.239 108.329 0.291
201912 0.271 108.420 0.329
202003 0.163 108.902 0.197
202006 0.312 108.767 0.378
202009 0.331 109.815 0.397
202012 0.445 109.897 0.534
202103 0.839 111.754 0.989
202106 0.603 114.631 0.693
202109 0.614 115.734 0.699
202112 2.909 117.630 3.259
202203 2.536 121.301 2.755
202206 1.510 125.017 1.592
202209 1.195 125.227 1.258
202212 1.343 125.222 1.413
202303 1.069 127.348 1.106
202306 0.785 128.729 0.804
202309 0.487 129.860 0.494
202312 0.194 129.419 0.198
202403 0.201 131.776 0.201

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


ProPhase Labs  (NAS:PRPH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ProPhase Labs's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=5.16/2.21
=2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ProPhase Labs was 14.95. The lowest was 0.57. And the median was 1.88.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ProPhase Labs Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ProPhase Labs (ProPhase Labs) Business Description

Traded in Other Exchanges
N/A
Address
711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
Executives
Morse Robert A. Jr. officer: Controller 711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White officer: Chief Financial Officer 191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr director 902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel 10 percent owner C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus 10 percent owner 188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch director 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady officer: Chief Accounting Officer 621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr officer: Chief Operating Officer PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard 10 percent owner 156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal 10 percent owner THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank director 104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin director
Mark A. Burnett 10 percent owner 40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley director, 10 percent owner, officer: Chairman, President, CEO C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo 10 percent owner 17 WOLCOTT COURT, BOSTON MA 02136